Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti-PD-1-Based Immunotherapy as Curative-Intent Treatment
CONCLUSIONS: Patients with dMMR/MSI-H locally advanced or low-lying rectal cancer who achieved cCR following anti-PD-1-based therapy had promising long-term outcomes. A prospective clinical trial with a larger sample size is required to further validate these findings.PMID:38498975 | DOI:10.6004/jnccn.2023.7096
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Authors: Jie-Hai Yu Le-En Liao Bin-Yi Xiao Xuan Zhang Ai-Wen Wu Yong Cheng Jing-Hua Tang Wu Jiang Ling-Heng Kong Kai Han Wei-Jian Mei Zhi-Gang Hong Wan-Jun Yang Dan-Dan Li Zhi-Zhong Pan Yun-Feng Li Xiao-Shi Zhang Pei-Rong Ding Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Clinical Trials | Gastroschisis Repair | Immunotherapy | Neoadjuvant Therapy | Rectal Cancers